OmniAb, Inc. (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.
Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021. Since its inception, the company has invested in multiple transgenic platforms—including OmniRat®, OmniMouse®, OmniChicken® and OmniClic®—to generate human and humanized antibodies with favorable developability profiles. These platforms are complemented by advanced bioinformatics and automation tools designed to streamline candidate selection and reduce time to clinic.
OmniAb serves a global client base of biotechnology and pharmaceutical companies, supporting antibody programs from early discovery through preclinical validation. The company maintains research facilities in North America and Europe, and its business development team collaborates closely with partners to tailor project portfolios and milestone-based arrangements.
Led by a management team with deep expertise in protein engineering, translational research and commercial strategy, OmniAb continues to expand its platform capabilities and strategic alliances. The company’s integrated approach aims to address key challenges in antibody discovery, including immunogenicity, manufacturability and target specificity, to deliver next-generation biologic therapeutics.
AI Generated. May Contain Errors.
Free OABI Stock Alerts